ライフサイエンスコーパス: tankyrase

1 ng with a poly(ADP-ribose) polymerase (PARP) tankyrase.

2 nhibition of the telomere-associated protein tankyrase.

3 dprtl3), and the telomere-associated protein tankyrase.

4 novel family of potent inhibitors for human tankyrases.

5 ies of potent flavone derivatives inhibiting tankyrases.

6 nd human TRF1 that mediates their binding to tankyrases.

7 Here, we show that tankyrase 1 activity at telomeres is controlled by a ubi

8 Tankyrase 1 ADP-ribosylates TRF1 in vitro, and its overe

9 Tankyrase 1 ADP-ribosylates TRF1, inhibiting its binding

10 Tankyrase 1 and 2 are poly(ADP-ribose) polymerases that

11 Tankyrase 1 and 2 have been shown to be redundant, drugg

12 rticularly the poly-ADP-ribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt

13 nhibitor 16 displays high target affinity on tankyrase 1 and 2 with biochemical and cellular IC50 val

14 1 (hTRF1) and its interacting proteins TIN2, tankyrase 1 and 2, and PINX1 have been implicated in the

15 TIN2 formed a ternary complex with TRF1 and tankyrase 1 and stabilized their interaction, an effect

16 nctions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2), regulators of the

17 Human TRF1 interacts with tankyrase 1 and tankyrase 2 proteins, two related member

18 inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2.

19 Overexpression of tankyrase 1 antagonizes both Mcl-1L-mediated cell surviv

20 We therefore sought to establish the role of tankyrase 1 at telomeres and to determine if tankyrase 2

21 bosyl)ation by tankyrase 1 without affecting tankyrase 1 automodification.

22 PARP activity in vitro, dependent on the GMD tankyrase 1 binding motif.

23 e 1 is reduced upon entry into mitosis, when tankyrase 1 binds to its other partners TRF1 (at telomer

24 We propose that inhibition of Tankyrase 1 could be therapeutically exploited in BRCA-a

25 Thus, interaction of Mcl-1L and Mcl-1S with tankyrase 1 could serve as a unique mechanism to decreas

26 Although tankyrase 1 down-regulates Mcl-1 protein expression, no

27 mosomes, telomeres rendered dysfunctional by tankyrase 1 engage in chromatid fusions almost exclusive

28 TAB182 coimmunoprecipitates with tankyrase 1 from human cells and serves as an acceptor o

29 Our findings indicate that tankyrase 1 has the unique capacity to promote both asse

30 nkyrase 1 with GMD in the cytosol sequesters tankyrase 1 in an inactive stable form that can be tappe

31 at K63-linked ubiquitin chains accumulate on tankyrase 1 in late S/G2 to promote its stabilization, a

32 nd TIN2 or SA1 abrogates the requirement for tankyrase 1 in mitotic progression.

33 We show that GMD is complexed to tankyrase 1 in the cytosol throughout interphase, but it

34 Overexpression of tankyrase 1 in the nucleus promotes telomere elongation,

35 as an acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in vitro.

36 In yeast and mammalian cells, tankyrase 1 interacts with both Mcl-1L and Mcl-1S, but d

37 We show that endogenous tankyrase 1 is a component of the human telomeric comple

38 Tankyrase 1 is a poly(ADP-ribose) polymerase (PARP) that

39 that the selectivity caused by inhibition of Tankyrase 1 is associated with an exacerbation of the ce

40 oughout interphase, but its association with tankyrase 1 is reduced upon entry into mitosis, when tan

41 Human tankyrase 1 is reported to ADP-ribosylate TRF1 and to do

42 ta-catenin turnover pathway as inhibition of tankyrase 1 led to high AEC axin levels, loss of pY654-b

43 These findings suggest that tankyrase 1 may act as a scaffold for large molecular ma

44 Analysis of truncated tankyrase 1 mutants indicated that the first 10 ankyrin

45 We show that either tankyrase 1 or 2 is sufficient to maintain telomere leng

46 Indeed, we show that GMD inhibits tankyrase 1 PARP activity in vitro, dependent on the GMD

47 However, it is not known how tankyrase 1 PARP activity is regulated.

48 We have shown that tankyrase 1 polymerizes through its sterile alpha motif

49 Tankyrase 1 recognizes a linear six-amino-acid degenerat

50 romotes telomere elongation, suggesting that tankyrase 1 regulates access of telomerase to the telome

51 ults showed that ADP-ribosylation of TRF1 by tankyrase 1 released TRF1 from telomeres and promoted te

52 We demonstrate that telomere elongation by tankyrase 1 requires the catalytic activity of the PARP

53 In addition to its telomeric localization, tankyrase 1 resides at multiple subcellular sites, sugge

54 Binding of partner proteins to tankyrase 1 usually results in their poly(ADP-ribosyl)at

55 st potent hit compound (X066/Y469) inhibited tankyrase 1 with an IC50 value of 250 nM.

56 We speculate that association of tankyrase 1 with GMD in the cytosol sequesters tankyrase

57 Furthermore, coexpression of tankyrase 1 with Mcl-1L or Mcl-1S decreased the levels o

58 rotected TRF1 from poly(ADP-ribosyl)ation by tankyrase 1 without affecting tankyrase 1 automodificati

59 roteins, TRF1 (an acceptor of PARsylation by tankyrase 1) and TIN2 (a TRF1 binding partner) each bind

60 Tankyrase 1, a human telomeric poly(ADP-ribose) polymera

61 Tankyrase 1, a human telomeric poly(ADP-ribose) polymera

62 at telomeres can be induced by inhibition of tankyrase 1, a poly(ADP-ribose) polymerase that is requi

63 itors of the potential pharmaceutical target tankyrase 1, a poly(ADP-ribose) polymerase.

64 Knockdown of tankyrase 1, a telomeric poly(ADP-ribose) polymerase cau

65 In cells depleted for tankyrase 1, a telomeric poly(ADP-ribose) polymerase, si

66 proposed to have activity similar to that of tankyrase 1, although tankyrase 2 function has been less

67 res requires the poly(ADP-ribose) polymerase tankyrase 1, but the mechanism that times its action is

68 ankyrase 2, like its closely related homolog tankyrase 1, can function as a positive regulator of tel

69 vivo, depletion of GMD led to degradation of tankyrase 1, dependent on the catalytic PARP activity of

70 hibition of the telomere-associated protein, Tankyrase 1, is also selectively lethal with BRCA defici

71 und, 22 (MN-64), showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling in

72 1.1 binds to the poly(ADP-ribose) polymerase tankyrase 1, preventing it from localizing to telomeres

73 oly(adenosine diphosphate ribose) polymerase tankyrase 1, sister telomere resolution is blocked.

74 entification of a closely related homolog of tankyrase 1, tankyrase 2, opens the possibility for a se

75 on of the positive telomere length regulator tankyrase 1, the TIN2/TINT1 complex remained on telomere

76 ng protein TRF1 and its interacting partners tankyrase 1, TIN2 and PINX1.

77 e (PARP) activity of its interacting partner tankyrase 1, which abolishes its DNA binding activity in

78 F8 conjugates K63-linked ubiquitin chains to tankyrase 1, while in G1 phase such ubiquitin chains are

79 Here we identify TAB182, a novel tankyrase 1-binding protein of 182 kDa.

80 Thus, telomeres may require a unique tankyrase 1-dependent mechanism for sister chromatid res

81 resolution of sister telomeres in mitosis in tankyrase 1-depleted cells.

82 e telomeric repeat binding factor 1, another tankyrase 1-interacting protein.

83 We discuss potential roles for tankyrase 1-mediated higher order complexes at telomeres

84 r binding partners, GMD is not PARsylated by tankyrase 1.

85 dependent on the catalytic PARP activity of tankyrase 1.

86 ,6-dehydratase (GMD) as a binding partner of tankyrase 1.

87 n cells overexpressing a PARP-dead mutant of tankyrase 1.

88 t also observed with the PARP-dead mutant of tankyrase 1.

89 in domain (comprising 24 ankyrin repeats) of tankyrase 1.

90 wo-hybrid screening and found cDNAs encoding tankyrase 1.

91 25 amino acids is sufficient for binding to tankyrase 1.

92 ve well conserved ankyrin repeat clusters in tankyrase 1.

93 hat can also be rescued by overexpression of tankyrase 1.

94 se delay can be rescued by overexpression of tankyrase 1.

95 Tankyrases 1 and 2 (TNKS1/2) are promising pharmacologic

96 Tankyrases 1 and 2 are members of the poly(ADP-ribose) p

97 This finding suggests that either mouse tankyrases 1 and 2 have redundant functions in telomere

98 07-LK (66) displayed high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM

99 Tankyrase-1 and -2 are closely related poly(ADP-ribose)

100 cks this motif and thus does not bind either tankyrase-1 or -2.

101 Using this method, PARP-1 and tankyrase-1 substrate proteins were labeled by a fluores

102 Several PARPs, such as PARP-1 and Tankyrase-1, are known to play important roles in DNA re

103 Poly(ADP-ribose) (pADPr), made by PARP-5a/tankyrase-1, localizes to the poles of mitotic spindles

104 haracterization of a second human tankyrase, tankyrase 2 (TANK2), which can also interact with TRF1 b

105 bition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2), regulators of the beta-catenin de

106 Tankyrase 2 (Tnks2) is a poly(ADP-ribose) polymerase (PA

107 These findings establish tankyrase 2 as a bona fide PARP, with itself and TRF1 as

108 To investigate a potential role for tankyrase 2 at telomeres, recombinant tankyrase 2 was su

109 n, and suggest the possibility of a role for tankyrase 2 at telomeres.

110 have assessed the in vivo function of mouse tankyrase 2 by germ line gene inactivation and show that

111 We report here crystal structures of human tankyrase 2 catalytic fragment in complex with a byprodu

112 Tankyrase 2 deficiency did result in a significant decre

113 in telomere length maintenance or that mouse tankyrase 2 differs from human tankyrase 2 in its role i

114 e inactivation and show that inactivation of tankyrase 2 does not result in detectable alteration in

115 ity similar to that of tankyrase 1, although tankyrase 2 function has been less extensively character

116 e, most marked in male mice, suggesting that tankyrase 2 functions in potentially telomerase-independ

117 or that mouse tankyrase 2 differs from human tankyrase 2 in its role in telomere length maintenance.

118 Overexpression of tankyrase 2 in the nucleus released endogenous TRF1 from

119 Binding of these inhibitors to tankyrase 2 induces specific conformational changes.

120 oids, we performed a systematic screening of tankyrase 2 inhibitory activity using 500 natural and na

121 Human tankyrase 2 is proposed to have activity similar to that

122 tankyrase 1 at telomeres and to determine if tankyrase 2 might have a telomeric function.

123 Tankyrase 2 poly(ADP-ribosyl)ated itself and TRF1.

124 Human TRF1 interacts with tankyrase 1 and tankyrase 2 proteins, two related members of the tankyra

125 le for tankyrase 2 at telomeres, recombinant tankyrase 2 was subjected to an in vitro PARP assay.

126 We show here by overexpression studies that tankyrase 2, like its closely related homolog tankyrase

127 of a closely related homolog of tankyrase 1, tankyrase 2, opens the possibility for a second PARP at

128 n complex with the catalytic domain of human tankyrase 2.

129 res bind to the nicotinamide binding site of tankyrase 2.

130 oly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2.

131 Tankyrase, a protein with homology to ankyrins and to th

132 Tankyrase, a telomeric poly(ADP-ribose) polymerase (PARP

133 939, which targets the enzymatic activity of tankyrase, acted to stabilize Axin2 levels in OLPs from

134 udy reveals a redox mechanism for regulating tankyrase activity and implicates PrxII as a targetable

135 tam-based nicotinamide mimetics that inhibit tankyrase activity, such as XAV939, are well-known, here

136 Here, we present evidence that tankyrase acts as a positive regulator of telomere elong

137 rase to IRAP involves the ankyrin repeats of tankyrase and a defined sequence ((96)RQSPDG(101)) in th

138 s disrupt the interaction between SH3BP2 and Tankyrase and describe rules for substrate recognition b

139 ay-based pooled CRISPR screen and identified tankyrase and its associated E3 ligase RNF146 as positiv

140 n contributes to the known colocalization of tankyrase and NuMA at mitotic spindle poles.

141 al cancers with APC mutation, PrxII binds to tankyrase and prevents its oxidative inactivation, there

142 rified NuMA as an RXXPDG-mediated partner of tankyrase and suggest that this interaction contributes

143 indings therefore reveal a critical role for tankyrase and the canonical Wnt pathway in maintaining l

144 Inhibition of tankyrase and various other components of the Wnt pathwa

145 deficiency could promote the degradation of tankyrases and consequent stabilization of Axin to antag

146 here structural differences are seen between tankyrases and other poly(ADP-ribose) polymerase (PARP)

147 lar mechanism that regulates the turnover of tankyrases and the possibility of targeting the stabilit

148 Flavones have been shown to inhibit tankyrases and we report here the discovery of more pote

149 an telomeric proteins, including TRF1, TRF2, tankyrase, and TIN2 have no recognized orthologs in budd

150 Thus, tankyrases appear to be master scaffolding proteins that

151 Direct binding of PrxII to tankyrase ARC4/5 domains seems to be crucial for protect

152 Tankyrases are ADP-ribosyltransferases that play key rol

153 Tankyrases are novel poly(ADP-ribose) polymerases that h

154 Tankyrases are poly(ADP-ribose) polymerases that have ma

155 We show that tankyrases are required for Notch2 to exit the plasma me

156 Using the ankyrin domain of tankyrase as a bait in a yeast two-hybrid screen, we als

157 is implies a common scaffolding function for tankyrases at each location, with specific tankyrase int

158 cell growth, indicating the ATRX-macroH2A1.1-tankyrase axis as a potential therapeutic target in ALT

159 Targeting the Wnt-tankyrase-beta-catenin pathway together with EGFR inhibi

160 Mutation of the tankyrase-binding motif (TBM) on TRF1 (13R/18G to AA) di

161 ponsive aminopeptidase), and TAB182 (182-kDa tankyrase-binding protein).

162 tent with this colocalization, we found that tankyrase binds specifically to a resident protein of GL

163 The mechanism by which tankyrase binds to diverse proteins has not been investi

164 Tankyrase binds to the telomeric protein TRF1 (telomeric

165 the poly(ADP-ribose) polymerase activity of tankyrase but apparently does not mediate the acute effe

166 he possibility of targeting the stability of tankyrases by antagonizing their interaction with USP25

167 Our results indicate that tankyrase can induce telomere elongation in human cells.

168 Tankyrases constitute potential drug targets for cancer

169 ssed tankyrase leading to formation of large tankyrase-containing vesicles, disruption of Golgi struc

170 Like ankyrins, tankyrase contains 24 ankyrin repeats in a domain respon

171 cal models on how other proteins as TIN2 and tankyrase contribute to regulate TRF1 function.

172 Quantitative analysis of the proteome of tankyrase double knockout cells using isobaric tandem ma

173 mall molecules that modulate the activity of Tankyrase enzymes and glycogen synthase kinase 3 beta (G

174 A PARP-deficient form of tankyrase failed to affect TRF1 and did not alter telome

175 yrase 2 proteins, two related members of the tankyrase family shown to have poly(ADP-ribose) polymera

176 5 domains seems to be crucial for protecting tankyrase from oxidative inactivation.

177 nts to novel potential strategies to inhibit Tankyrase function in oncogenic Wnt signaling.

178 e PARP activity in vitro, with both TRF1 and tankyrase functioning as acceptors for adenosine diphosp

179 Potent and selective inhibitors of tankyrases have recently been characterized to bind to a

180 along the length of the telomere (TRF1/TIN2/tankyrase in humans and Rap1/Rif1/Rif2 in budding yeast)

181 Long-term overexpression of tankyrase in telomerase-positive human cells resulted in

182 Overexpression of tankyrase in the nucleus diminished the level of unmodif

183 egulation of PTEN and highlighted a role for tankyrases in the PTEN-AKT pathway that can be explored

184 the PARP-dependent Axin1 degradation through tankyrase inactivation.

185 ike naive states with only WNT, MEK/ERK, and tankyrase inhibition (LIF-3i).

186 Our data suggest that tankyrase inhibition could serve as a novel strategy to

187 r the level of AXIN protein stabilization by tankyrase inhibition is sufficient to impact tumor growt

188 Tankyrase inhibition promoted a stable acquisition of a

189 an undifferentiated state may be blocked by tankyrase inhibition.

190 Mice given a tankyrase inhibitor (50 mg/kg orally) daily for 7 days b

191 XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in v

192 elationship study was conducted based on the tankyrase inhibitor JW74 (1).

193 entification of a novel potent and selective tankyrase inhibitor that binds to both the nicotinamide

194 ipophilic efficiency, NVP-TNKS656 is a novel tankyrase inhibitor that is well suited for further in v

195 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinet

196 Flavone has been previously identified as a tankyrase inhibitor, and to further elucidate whether ta

197 Tankyrase inhibitor, but not porcupine inhibitor, which

198 In the xenograft model most sensitive to tankyrase inhibitor, COLO-320DM, G007-LK inhibits cell-c

199 nct small-molecule Wnt pathway inhibitors (a tankyrase inhibitor, XAV-939, and the U.S. Food and Drug

200 Tankyrase inhibitor-induced stabilization of angiomotins

201 uinoxaline 41, a highly potent and selective tankyrase inhibitor.

202 Interest is mounting in tankyrase inhibitors (TNKSi), which destabilize beta-cat

203 identification of more potent and selective tankyrase inhibitors 22 and 49 with improved pharmacokin

204 asis for rational development of flavones as tankyrase inhibitors and guides the development of other

205 nostic and safety concerns to be overcome as tankyrase inhibitors are advanced into the clinic.

206 We show that novel tankyrase inhibitors completely block ligand-driven Wnt/

207 lish proof-of-concept antitumor efficacy for tankyrase inhibitors in APC-mutant CRC models and uncove

208 d cell lines, demonstrating the potential of tankyrase inhibitors in oncology.

209 h signaling is commonly activated in cancer, tankyrase inhibitors may have therapeutic potential in t

210 33 and resulted in highly potent, selective tankyrase inhibitors that are novel three pocket binders

211 All identified tankyrase inhibitors were flavones.

212 modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic prope

213 developed potent and specific small-molecule tankyrase inhibitors, G007-LK and G244-LM, that reduce W

214 uggests clues for the further development of tankyrase inhibitors.

215 tures gave instant access to a new series of tankyrase inhibitors.

216 We showed that tankyrases interact with and ribosylate PTEN, which prom

217 r tankyrases at each location, with specific tankyrase interaction partners conferring location-speci

218 Tankyrase is a novel signaling target of mitogen-activat

219 Taken together, tankyrase is a novel target of MAPK signaling in the Gol

220 orescence to show in 3T3-L1 fibroblasts that tankyrase is a peripheral membrane protein associated wi

221 Subsequent studies revealed that most tankyrase is actually extranuclear, but a discordant pat

222 ere we report that the inhibition of TRF1 by tankyrase is in turn controlled by a second TRF1-interac

223 us, regulation of the levels and activity of tankyrases is mechanistically important in controlling W

224 Both tankyrase isoforms interact with a highly conserved doma

225 cotinamide, and with selective inhibitors of tankyrases (IWR-1) and PARPs 1 and 2 (olaparib).

226 h SAM-dependent association of overexpressed tankyrase leading to formation of large tankyrase-contai

227 We speculate that tankyrase may be involved in the long term effect of the

228 Inhibition of tankyrases may offer a novel approach to the treatment o

229 Tankyrase-mediated ADP-ribosylation inhibits binding of

230 We propose that tankyrase-mediated ADP-ribosylation of TRF1 opens the te

231 Tankyrase-mediated PARylation marks protein targets for

232 timulated cells, Axin is rapidly modified by tankyrase-mediated poly(ADP-ribosyl)ation, which promote

233 omeric repeats in vitro [5], suggesting that tankyrase might regulate TRF1 and therefore control telo

234 lar poly(ADP-ribose) polymerases (PARPs) and tankyrases modulates chromatin structure, telomere elong

235 Inhibition of tankyrase or depletion of RNF146 stabilizes angiomotins.

236 flavones show up to 200-fold selectivity for tankyrases over ARTD1.

237 also found the RXXPDG motif in six candidate tankyrase partners, including the nuclear/mitotic appara

238 Finally, tankyrase polymers are dissociated efficiently by poly(A

239 These features make tankyrases potential targets for treatment of cancer.

240 ic ablation or pharmacological inhibition of tankyrase prominently suppresses YAP activity and YAP ta

241 Our targets are the tankyrase proteins (TNKS), poly(ADP-ribose) polymerases

242 ripping TRF1 off the telomeres by expressing tankyrase reduced telomere recruitment of not only TIN2

243 such rules paves the way to identifying all Tankyrase-regulated pathways in cells.

244 the use of 41 to investigate the biology of tankyrase, revealing the compound induced growth inhibit

245 o and in cells, whereas IWR1 and AZ-6102 are tankyrase selective.

246 As has been noted for tankyrase, sequence analysis of the Adprtl1 protein sugg

247 gative regulators of YAP signaling, as novel tankyrase substrates.

248 Tankyrase (TANK1) is a human telomere-associated poly(AD

249 we report characterization of a second human tankyrase, tankyrase 2 (TANK2), which can also interact

250 nt of wild-type embryos with an inhibitor of Tankyrase that stabilizes Axin proteins also causes inhi

251 Angiomotins physically interact with tankyrase through a highly conserved motif at their N te

252 compound 8 was identified as an inhibitor of tankyrases through a combination of substructure searchi

253 The poly(ADP-ribose) polymerase (PARP) Tankyrase (TNKS and TNKS2) is paramount to Wnt-beta-cate

254 We identify the ADP-ribosyltransferase tankyrase (TNKS) and the 19S assembly chaperones dp27 an

255 he poly(ADP-ribose) polymerase (PARP) enzyme Tankyrase (TNKS) antagonizes destruction complex activit

256 Inhibitors of the ADP-ribose polymerase Tankyrase (Tnks) have become lead therapeutic candidates

257 sis coli (APC) and the ADP-ribose polymerase Tankyrase (Tnks) have evolutionarily conserved roles in

258 molecule inhibitors of the Wnt pathway, and tankyrase (TNKS) inhibition has been demonstrated to ant

259 Tankyrase (TNKS) is a Golgi-associated poly-ADP-ribose p

260 Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PAR

261 Tankyrase (TNKS) is a telomere-associated poly-ADP ribos

262 telomere protection enzymes belonging to the tankyrase (Tnks) subfamily of poly(ADP-ribose) polymeras

263 ed by its poly-ADP-ribosylation catalyzed by tankyrase (TNKS), which requires the direct interaction

264 Axin and find that the ADP-ribose polymerase Tankyrase (Tnks)--known to target Axin for proteolysis-r

265 6 directly interacts with the PAR polymerase tankyrase (TNKS).

266 Tankyrases (TNKS) play roles in Wnt signaling, telomere

267 The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of beta-ca

268 Tankyrases (TNKS1 and TNKS2) are proteins in the poly AD

269 Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8

270 tent and isoform selective toward inhibiting tankyrases (TNKSs) than the "standard" inhibitor 1 (XAV9

271 onstrate that polymerization is required for Tankyrase to drive beta-catenin-dependent transcription.

272 eric state supports PARP activity and allows Tankyrase to effectively access destruction complexes th

273 The binding of tankyrase to IRAP involves the ankyrin repeats of tankyr

274 TRF1 binding allows tankyrase to regulate telomere dynamics in human cells,

275 ells, whereas IRAP binding presumably allows tankyrase to regulate the targeting of IRAP.

276 We found that USP25 directly interacted with tankyrases to promote their deubiquitination and stabili

277 Potencies of the active flavones toward tankyrases vary between 50 nM and 1.1 muM, and flavones

278 Tankyrase was expressed in 85% of the glioblastoma tissu

279 Recombinant tankyrase was found to have PARP activity in vitro, with

280 The poly(ADP-ribose) polymerase tankyrase was originally described as a telomeric protei

281 Furthermore, tankyrases were up-regulated and negatively correlated w

282 Tankyrase, which poly(ADP-ribosyl)ates and thereby desta

283 We identified PTEN as a novel substrate of tankyrases, which are members of the poly(ADP-ribose) po

284 We further colocalized tankyrase with GLUT4 storage vesicles in the juxtanuclea

285 inhibitor, and to further elucidate whether tankyrases would be inhibited by other flavonoids, we pe